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ABSTRACT
The aim of clinical effectiveness research using repositories of electronic health records is to identify
what health interventions ’work best’ in real-world settings. Since there are several reasons why the
net benefit of intervention may differ across patients, current comparative effectiveness literature
focuses on investigating heterogeneous treatment effect and predicting whether an individual might
benefit from an intervention. The majority of this literature has concentrated on the estimation of
the effect of treatment on binary outcomes. However, many medical interventions are evaluated
in terms of their effect on future events, which are subject to loss to follow-up. In this study, we
describe a framework for the estimation of heterogeneous treatment effect in terms of differences
in time-to-event (survival) probabilities. We divide the problem into three phases: (1) estimation
of treatment effect conditioned on unique sets of the covariate vector; (2) identification of features
important for heterogeneity using an ensemble of non-parametric variable importance methods; and
(3) estimation of treatment effect on the reference classes defined by the previously selected features,
using one-step Targeted Maximum Likelihood Estimation. We conducted a series of simulation
studies and found that this method performs well when either sample size or event rate is high enough
and the number of covariates contributing to the effect heterogeneity is moderate. An application of
this method to a clinical case study was conducted by estimating the effect of oral anticoagulants on
newly diagnosed non-valvular atrial fibrillation patients using data from the UK Clinical Practice
Research Datalink.
Keywords Survival Analysis ·Machine Learning · Heterogeneous Treatment Effect · Targeted Maximum Likelihood
Estimation
1 Introduction
In medical studies, we want to use empirical evidence to estimate the effect of treatment: such as a drug or a procedure.
The gold standard for the evaluation of treatment effect is the randomized control trial (RCT) since its randomisation
minimises bias and maximises our ability to identify causality. However, it has become clear that it is not possible to
depend on RCTs for all the information needed on the effectiveness of medical interventions since they do not represent
real-world populations or settings and tend to be too short to detect long-term effects. Furthermore, RCTs are designed
to estimate the average effect of interventions and might, therefore, not be able to inform decisions about individual
patients encountered in clinical practice. Recently, there has been an explosion of observational studies where large
repositories of routinely collected health data are used to customize estimates of treatment effect for individuals. In
this study, we focus on the estimation of heterogeneous treatment effect (HTE) for binary treatment options (treated vs
control) on time-to-event (survival) outcomes using right-censored data. These estimates account for loss to follow-up
and allow for the measurement of the long-term effect of interventions.
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Commonly used measures of treatment effect in terms of survival outcomes are the hazard ratio, the difference in
length of survival time, and the difference in survival probability, of which only the latter two are absolute effect
measures. Current standards for the reporting of findings in experimental studies (CONSORT[1]) and observational
studies (STROBE[2]) recommend reporting both absolute and relative measures of effect whenever possible. In
spite of this recommendation, the majority of previous clinical survival analyses report hazard ratios under Cox
proportionality assumptions [3]. This is not ideal for the estimation of HTE since absolute effects provide more relevant
information for clinical decisions and should be used when describing personalised treatment effects [4]. Furthermore,
the proportionality of hazards assumption does not always hold. Here, we choose the difference in survival probabilities
as the primary treatment effect measure and convert it into a hazard ratio when required for comparison with other
studies.
The estimation of HTE in survival analysis requires us to simultaneously adjust for selection bias from both censoring
and treatment allocation and find the reference class associated with an individual patient for which reliable statistics
can be compiled. That is, our goal is to estimate a conditional average treatment effect (CATE) for all heterogeneous
reference classes. Methods for HTE estimation generally fall into one of three categories: transformed outcome
regression [5], conditional mean regression [6, 7], and double-robust estimators [8].
The transformed outcome approach creates a new target variable that combines the observed outcomes weighted by the
inverse of the probability that a patient would receive treatment given patient covariates (propensity score). It has the
property that under the assumption of unconfoundness[5] [9], the estimation of CATE for each unique set of covariates
is unbiased, although at the cost of high variance.
Conditional mean regression models aim at accurately estimating condition mean functions for the potential outcomes
and deriving treatment effect as the difference between these potential outcomes. These methods can suffer from bias
if the outcome model is misspecified, particularly in areas of the covariate space where there is no overlap between
intervention and control. Recent applications of conditional mean regression models in survival analysis report the
effect either as the difference in length of survival time using random forest [10, 11]; or in terms of survival probability
using a deep neural network with Cox proportionality of hazards assumption (DeepSurv[12]), a deep neural network
accepting competing risks (DeepHit[13]), a deep recurrent neural network (DRSA[14]), or Super-learner [15].
Double-robust estimators refer to a class of procedures that combine outcome models with propensity score models. In
the survival context, they are double-robust in the sense that the treatment effect estimator is consistent if either the
propensity score and the conditional probability of censoring are consistently estimated, or the conditional survival
probability of failure event is consistently estimated. These estimators enjoy flexible regression tools such as those used
in conditional mean regression models and are often statistically more efficient (unbiased) due to the use of propensity
scores. Existing frameworks for efficient causal effect estimation include the targeted maximum likelihood estimation
(TMLE)[16], the Quasi-Oracle R-learner[17], and the recent Non-stationary Gaussian Process Regression (NSGP)
[18] which assumes a non-stationary Gaussian process prior as the initial estimator instead of the conditional mean in
TMLE. Although most methods developed in this class are aimed at uncensored outcomes, it is possible to use TMLE
to estimate average survival probability at a single time point [19]. Furthermore, recent development of one-step TMLE
[20] enables the estimation of a monotonic average treatment effect curve.
Investigating the performance of double-robust estimators in survival causal inference motivates this paper. To estimate
HTE as the difference in survival probabilities, we face three challenges: 1) model the unobserved survival probability
using longitudinal data; 2) identify key covariates contributing to the heterogeneity of the survival treatment effect;
and 3) form double-robust estimates of CATE. We address the first challenge by converting the survival dataset into
a counting process (i.e., longitudinal data series with binary outcomes) and computing the cumulative hazard rate
to get the survival probabilities. This allows us to circumvent the Cox proportionality assumption as well as to use
data-adaptive outcome models such as Super-learner or Deep learning techniques. In this study, we choose Super-learner
algorithms on moderate-dimensional data and leave high dimensional deep learning techniques for future work. To
address the second challenge, we use an ensemble of standard methods used to identify variable importance in causal
inference, including Lasso[21], Causal Forest[22] and permutation test using BART[23]. The Kneedle Algorithm[24] is
applied to each method to provide the threshold for variable inclusion. Finally, CATE is estimated for the reference
classes defined by the selected features using kernel-based local averaging [25], and selection bias is adjusted for using
one-step TMLE.
An outline of this paper is as follows. Section 2 describes the methodology to estimate the survival treatment effect. In
Section 3, we introduce a set of simulation scenarios under different data dimensions, sizes, confounding levels, and
event rates. Sections 4 provides a case study that estimates the effect of anticoagulants in atrial fibrillation patients. We
end with a discussion.
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2 Targeted survival heterogeneous effect estimation
2.1 Definition of survival treatment effect
To formalize the framework for causal inference in survival analysis, we follow the notations in previous studies
[16, 26, 27]. Suppose we observe a sample O of n individuals generated by an unknown distribution P0:
O := (Xi, Ai, Yi, Ti = min(ts,i, tc,i)), i = 1, 2, . . . , n,
where Xi = (Xi,1, Xi,2, . . . , Xi,j), j = 1, 2, . . . , J are baseline covariates; Ai is the exposure condition, Ai = 1 if
observation i receives the treatment and Ai = 0 otherwise; Yi(t) denotes the outcome at time t, Yi = 1 if i experienced
an event and Yi = 0 otherwise; Ti is the observed event/censoring time and is determined by the potential event
occurrence time, ts,i, or censor time tc,i. We can define the conditional survival function S(t)i at time t for i as:
S(ti = t|Ai, Xi) := P (ti > t|Ai, Xi), t = 1, 2, . . . ,Θ,
where Θ is the end of follow up period. Using the potential outcomes framework by Rosenbaum and Rubin [9], we
define unconfoundness by assuming: 1) the treatment assignment A is independent of event/censoring time T given
X; and 2) the censoring is non-informative (coarsening at random). Under these assumptions, the conditional average
treatment effect (CATE), ψ(x, t), can be defined as:
ψ(X, t) = EX=x
[
E[S(t)|A = 1, X = x]− E[S(t)|A = 0, X = x]]. (1)
A reliable estimation of CATE is straightforward when there are large amount of observations for each unique set of
covariates [28] X = x. However, this is unlikely in common medical studies. For a single observation with X = x,
equation (1) represents an individual treatment effect (ITE). For the purpose of this manuscript, ψ(X, t) is called ITE
when x represents the full covariate vector. The aim of this study is to identify important features X contributing to the
heterogeneity of ψ(X, t), and form double-robust estimations of CATE for these selected reference classes.
Figure 1: Diagram depicting heterogeneous effect estimation framework.
2.2 The framework
Figure 1 depicts the proposed framework for CATE estimation, we describe the three steps in the sections below.
Step 1. Estimate of individual treatment effect Individual treatment effects are estimated by fitting outcome models
on treated and control samples: f(t|A = 1, X) and f(t|A = 0, X), t = 1, 2, . . . ,Θ; then, we calculate potential
outcomes using these models as E[S(t)i] = f(t|A = 1, xi) and E[S(t)i] = f(t|A = 0, xi). This two-model approach
encodes the different relevant explanatory variables for treated and control outcomes and has been proved to improve
the potential outcome estimation accuracy [18].
We start by converting the original survival data into a counting process: a sequence of binary outcomes over time. We
then use Super-learner to estimate the conditional hazard rate h(t)i for each observation i at each time t as:
h(t)i := P (ti ∈ (t− 1, t]|ti > t− 1, Ai, Xi),
where ti is the observed event time for i. The potential survival probabilities are then derived via the probability chain
rule:
S(t)i =
∏
T :T≤t
(1− h(T )i),
and plug into equation (1) to get the initial treatment effect estimation ψˆ(Xi, t) for i at time t.
3
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The accuracy of this estimation at each time t is computed using normalized root-mean squared error (NRMSE):
NRMSE(t) =
1
ψ¯(t)
√√√√ n∑
i=1
(
ψˆ(Xi, t)− ψ(Xi, t)
)2
, t = 1, 2, . . . ,Θ,
where ψ¯(t) is the estimated average treatment effect at time t and ψ(Xi, t) represents the unobserved true individual
treatment effect.
Step 2. Identification of features contributing to heterogeneity of treatment effect Given the estimated ITE, we
seek to identify which features contribute to the heterogeneity of treatment effect. We model ITE using machine learning
algorithms and define important features as those that contribute most to the reduction of the model prediction error.
The regression methods employed here are: Bayesian Additive Regression Trees (BART)[23], Adaptive Lasso (AL)[29],
Elastic Net (EN)[30] and Causal Forest (CF)[22]. Previous studies found AL and EN give consistent selections of
covariates compared to the standard Lasso.[29, 30] Alternatively, we could have chosen to model ITE within strata of
similar propensity score[31]. However, this was not chosen since recent work has demonstrated the propensity score
matching (PSM) may result in increased covariate imbalance in observational studies.[32]
The feature identification procedure is as follows:
1. Regress the estimated ITEs at the end of follow-up period Θ on covariates X using model f(·):
ψˆ(X,Θ) = f(X);
2. Calculate the variable importance score Sj for features Xj , j = 1, 2, . . . , D, where D is the number of
features;
3. Rank features according to their importance score Sj in descending order and assign the rank Rj to each Xj ;
4. Construct an importance score curve using ordered pairs (Sj , Rj);
5. Use Kneedle Algorithm[24] to identify the Knee Point1, and label features with a higher importance score than
the Knee Point as having significant contribution to the heterogeneous effect.
Step 3. Target estimation of CATE Kernel-based local averaging[25] is used to calculate CATE associated with the
reference classes defined by the previously selected features. Let X∗ be a selected feature, we can divide the population
into Q strata (q = 1, 2, . . . , Q) based on the value of X∗, then for each stratum q (q = 1, 2, . . . , Q), we calculate the
marginal conditional average treatment effect (MCATE) as:
ψq(X
∗, t) =
1
hq
hq∑
i=1
ψ∗(Xi, t|X∗∈q), t = 1, 2, . . . ,Θ,
where hq is the number of observations in stratum q and ψ∗(·) is the one-step TMLE adjusted treatment effect. To get
ψ∗(·), we adjust the initial estimator ψˆ(·) in step one with conditional censoring probability, P (C > t|A,X), and the
propensity score, P (A = 1|X), where t = 1, 2, . . . ,Θ and C is the observed censor time. We estimate both probability
scores and conduct the adjustment following the previous study[20]. The accuracy of CATE estimations is measured by
absolute percentage bias:
%Bias(t) =
∣∣∣∣ ψˆq(X∗, t)− ψq(X∗, t)ψˆq(X∗, t)
∣∣∣∣, t = 1, 2, . . . ,Θ, and, q = 1, 2, . . . , Q.
All computations were carried out using R software. For ITE, censoring probability and propensity score estimations,
we use R package SuperLearner[33], with an ensemble of generalized additive models (R package gam[34] at degrees
of freedom at 0.5), multivariate adaptive regression splines (R package earth[35]) and elastic-net regularized generalized
linear models (R package glmnet[36]). The training of Super-learner is cross-validated with 10 folds. To calculate
variable importance, we use R package grf [37] for causal forest, BartMachine[23] for BART, and glmnet[36] for
Adaptive Lasso and Elastic Net. For one-step TMLE adjustment, we use package MOSS[38].
1One can think Knee Point as the inflection point at the local minimum (if the importance score curve is convex) or the local
maximum (if the curve is concave). Please refer to Appendix A for more detail.
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3 Experiments
3.1 Design of experiments
To explore the finite-sample performance of our proposed method, we conduct simulations under multiple scenarios.
Survival datasets are generated following previous literatures [20, 39, 40] using:
• D − 1 continuous covariates X1, X2, X3, X5, X6, . . . , XD ∼ Unif(0, 1);
• a binary covariate X4 ∼ Binom(0.5);
• a binary exposure A ∼ Binom(odds/(1 + odds)), where odds = 0.25 + β(X1 + X2) and β controls the
level of confounding;
• survival time T ∼ exp(τ(A,X)), where
τ(A,X) = (A(X1 + 3X5 + (1− 3X2)2 +X3X4) +X1 +X2 + . . .+XD)/r;
The component X1 + 3X5 + (1− 3X2)2 +X3X4 controls the heterogeneous effect. It combines two linear
features of different scale, X1 and 3X5, a non-linear feature (1 − 3X2)2, and an interaction term X3X4.
The denominator r controls the magnitude of τ(A,X), a larger r leads to lower event probability and longer
survival time. r also controls the event rate R = number of events / number of observations. In this design,
an observation with treatment condition A = 1 will have ceteris paribus lower survival probability than A = 0;
• censor time C ∼Weibull(1 + 0.2X1, 50), which is lightly confounded by X1; and
• survival outcome Y = I(T ≤ C), where I is an indicator function, I = 1 if T ≤ C and I = 0 otherwise.
The outcome is confounded on covariates X1 and X2. Thus, the true survival probability at t is S(t|A,X) =
exp(−tτ(A,X)).
A series of experiments are conducted by changing the following simulation parameters:
• Sample size, N (default: N = 3, 000; range: N = 1, 000, 3, 000, 9, 000 and 15, 000);
• Dimension, D (default: D = 10; range: D = 8, 10, 14, 20, 30);
• Level of confounding, β (default: β = 0.5; range: β = 0, 0.5, 1.0, 2.0);
• Event rate,R (default: R = 10%; range: R = 2.5%, 5.0%, 10%, 15%, 20%, 30%); and
• Number of subgroups, M (default: M = 10; range: 1, 5, 15, . . . , 50). When M = 1, we make estimations
using the whole sample and get the average treatment effect (ATE); when M > 1, the subgroup size for a given
continuous covariate will roughly equals N/M since we simulate continuous covariates using the uniform
distribution.
The default values have been chosen as typical values encounter in medical studies and previous literature.
In the first set of experiment, we examine the accuracy of feature identification under different values of N,D, β andR.
The impact of changing N and D is examined with default values β = 0.5 andR = 10%. The impact of changing β
andR is examined with default values N = 3, 000 and D = 10. Two measures are used for benchmarking: 1) positive
predictive value (PPV = TP/(TP + FP)) and 2) true positive rate (TPR = TP/P), where P is the number of true
features explaining the heterogeneous effect, TP is the number of correctly predicted features, and FP is the number of
falsely predicted features. The second experiment examines the accuracy of CATE estimations under different values of
N,D, β,R and M .
3.2 Results of experiments
In this section, we present the experiment results for the first 12 time points (Θ = 12) in all scenarios.
Experiment 1 - Feature identification accuracy We start by examining the distribution of the initial ITE estimations
under different effect sizes. Figure 2 depicts the true and estimated ITEs using samples under default scenarios with
R = 20%, 10%, 5% and 2.5% 2. Overall, we found ITEs disperse over time with increasing effect heterogeneity. The
scale of the effect heterogeneity is significantly higher in high event rate scenarios. When t = 12, the ATE (indicated
by cross marks) forR = 20% is 8.4 times higher than theR = 2.5% (−11.8% and −1.4%).
2We did not depict the ITE distributions under other scenarios (as they all have the same event rate by design) or the distributions
after TMLE (as TMLE is not used for correcting individual estimations). In Appendix B, we can see the NRMSE after TMLE is
worse than the NRMSE directly from the Super-learner estimation.
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Figure 2: Distribution of true ITE (grey violin plots) and estimated effects from Super-learner (red violin plots). The vertical axis shows the
event rates and NRMSE of the estimation. The horizontal axis shows the value of ITE. The grey and red cross marks indicate the true and estimated
average treatment effects. We depicted the ITEs at time 1,6 and 12 from one of 50 simulations under default settings of sample size(N = 3, 000),
low confounding level(β = 0.5) and feature dimension(D = 10). Abbreviation: ITE: Individual Treatment Effect, NRMSE: Normalised Root
Mean Square Error
The accuracy of initial ITE estimator (in terms of NRMSE) is examined across different values of N,D, β andR. We
notice that higher levels of confounding (β) raise NRMSE only by a small amount, for example: the NRMSE(t = 12)
is 0.482 at β = 0 and 0.521 at β = 2, but the %bias(t = 12) of the ATE is 8.41% and 24.55% respectively.
Higher dimensions (D) also result in worse NRMSE, for example: NRMSE(t = 12) doubles when D = 30 compared
to D = 8 given default values for other variables. However, the negative impact of higher dimensions can be offset
by increasing the sample size. We observe NRMSE was halved as N increased from 1, 000 to 15, 000. Lastly, lower
event rates were related to higher NRMSE, which doubled from R = 20% to 2.5%. It is also worth noting that the
aforementioned trend also holds for the %bias of ATE (Indicated by the cross marks in Figure 2).
The accuracy of feature identification is most affected by data dimension (D), and sample size (N). Given default values
of event rate and confounding, Table 1 illustrates a larger sample size is required to correctly identify all contributing
features. When the sample size is 3, 000, BART is the best performing algorithm in terms of PPV and TPR. For D > 10,
the PPV and TPR drop below 50% across all algorithms. At the largest sample size(N = 15, 000), the performance of
BART was lifted significantly after D > 10.
Experiment 2 - CATE estimation accuracy We illustrate CATE estimation accuracy by averaging the %Bias of
50 subgroups of size 300 for X2 ∈ [0, 0.1) under default simulation settings. Panels (a) to (d) in Figure X illustrate
the %Bias as a function of follow-up time for different levels of confounding (a), dimension (b), event rate (c) and
subgroup size (d). There is no notable change in bias over time, although standard errors increase with time due to
smaller sample sizes (see Appendix X). As expected, low confounding, low dimension or high event rate scenarios
enjoy higher estimation accuracy. The subgroup size, on the other hand, is not a major factor for CATE accuracy(if the
initial ITEs are accurately estimated, then taking the average of these ITEs will be accurate for any subgroup sizes).
Both event rate and data dimension have an important impact on CATE accuracy.
Panels (e-g) examine the impact of event rate in combination with confounding (e), dimension (f) and sample size(h).
WhenR ≥ 20%, the bias is contained within 10% for all examined situations except the case of D = 30. ForR ≤ 5%,
the CATE estimation quality is most affected by D with bias increasing significantly to 20%− 30%. Sample size seems
6
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Table 1: Diagnostic statistics for contributing feature identification (%)
TPR Decomposition ∆: N = 9, 000 to N = 15, 000
N D PPV TPR X1 X2 X3 X4 X5 PPV TPR X1 X2 X3 X4 X5
15
00
0
A
da
pt
iv
e
L
as
so 8 89 55 25 25 50 75 100 26 8 -25 -30 25 25 45
10 68 50 50 75 50 25 50 14 2 -10 20 45 -25 -20
14 42 35 50 75 0 0 50 -3 -5 15 20 -30 -40 10
20 28 30 0 75 25 25 25 -2 0 -25 35 10 -15 -5
30 13 20 50 0 25 25 0 -10 -4 25 -15 15 0 -45
BA
R
T
8 83 55 50 100 25 25 100 6 3 30 5 -5 -15 0
10 86 50 25 100 25 25 100 11 -11 -20 5 -5 -35 0
14 52 75 100 100 50 25 100 -10 30 75 15 40 10 10
20 43 65 25 100 50 50 100 1 25 5 25 30 30 35
30 25 55 25 100 25 50 100 1 31 10 60 0 30 55
C
au
sa
lF
or
es
t 8 57 60 75 50 75 75 25 -1 1 0 5 5 10 -15
10 39 40 75 0 50 50 25 -5 -16 15 -45 -15 -15 -20
14 48 45 50 25 50 75 25 13 0 0 -5 -5 25 -15
20 33 15 0 25 0 50 0 7 -18 -35 10 -45 20 -40
30 17 10 0 25 0 25 0 4 -7 -5 0 -15 0 -15
E
la
st
ic
N
et
8 89 55 25 25 50 75 100 25 11 -25 -30 25 30 55
10 68 50 50 75 50 25 50 14 0 -10 15 40 -25 -20
14 42 35 50 75 0 0 50 -3 -5 15 20 -30 -40 10
20 28 30 0 75 25 25 25 -2 0 -25 35 10 -15 -5
30 11 20 50 0 25 25 0 -12 -3 25 -15 15 0 -40
∆: N = 3, 000 to N = 9, 000
30
00
A
da
pt
iv
e
L
as
so 8 62 47 57 50 27 50 50 2 0 -7 5 -2 0 5
10 50 47 30 57 37 40 70 4 1 30 -2 -32 10 0
14 43 31 23 43 33 27 27 2 9 12 12 -3 13 13
20 26 21 27 10 23 20 23 3 9 -2 30 -8 20 7
30 15 12 10 13 10 13 13 8 12 15 2 0 12 32
BA
R
T
8 82 54 37 93 3 43 93 -5 -2 -17 2 2 -3 7
10 66 47 40 83 10 40 63 9 13 5 12 -5 15 37
14 50 43 40 57 20 47 53 13 2 -15 28 -10 -32 37
20 32 33 30 47 13 43 30 10 7 -10 28 7 -23 35
30 21 24 27 37 13 13 30 4 0 -12 3 -13 7 15
C
au
sa
lF
or
es
t 8 65 45 47 43 50 43 40 -7 14 28 2 20 22 0
10 54 43 47 30 53 47 37 -11 13 13 15 12 18 8
14 38 39 37 47 53 23 37 -3 6 13 -17 2 27 3
20 23 25 27 33 13 30 23 3 8 8 -18 32 0 17
30 12 15 23 17 13 3 20 1 2 -18 8 2 22 -5
E
la
st
ic
N
et
8 61 45 53 50 27 47 50 4 -1 -3 5 -2 -2 -5
10 51 47 33 57 37 40 70 2 3 27 3 -27 10 0
14 43 33 27 43 37 30 30 1 7 8 12 -7 10 10
20 26 19 30 10 13 20 20 3 11 -5 30 2 20 10
30 18 15 23 17 10 13 10 5 8 2 -2 0 12 30
Each cell on the LHS of the vertical line is the diagnostics metrics. For each dimension and sample size, we highlight values with the best PPV
and TRP in green. The TPR decomposition shows the percentage of times when the true feature is identified across all samples (we bold the
best value on each row). On the RHS, we give the difference (∆) in metrics by increasing the sample size from a smaller value to a bigger one.
All metrics are averaged across 50 samples.
Abbreviations: PPV, Positive Predictive Value; TPR, True Positive Rate; N , Sample Size; D, Feature Dimension.
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to have a small impact after controlling dimension and confounding level. Only at R = 2.5%, we see a significant
uplift in bias for N ≤ 3, 000.
Panels (i-j) examine the impact of dimension in combination with sample size (i) and confounding (j). By controlling
R = 10%, increasing the sample size is not very effective to reduce bias for high dimension scenarios. However, the
bias is lower when a high-dimension scenario occurs with low confounding. A complete list of the results related to
these experiments can be found in Appendix B.
4 Case study
4.1 Data Source
We provide a case study to illustrate the application and utility of this framework. We conducted a retrospective
observational cohort study that estimates the effect of oral anticoagulants for the prevention of stroke for patients with
newly diagnosed non-valvular atrial fibrillation (AF). This is part of a larger project on investigating the comparative
effectiveness of anticoagulants that makes use of the UK’s Clinical Practice Research Datalink (CPRD)[41] and includes
the primary care database (GOLD) linked to the Hospital Episode Statistics (HES) Admitted Patient Care, the HES
Outpatient Data, the Office for National Statistics (ONS) Mortality data and the Patient Level index of Multiple
Deprivation. The cohort consisted of patients with a diagnosis of AF (either in CPRD or HES datasets) between
1st-Mar-2011 and 31-July-2017, 18 years or over at time of first diagnosis, meeting CPRD’s research quality indicators,
registered with CPRD for at least one year before their initial diagnosis, and who had their records linked to HES
data. Patients with a history of AF or with a record for a valve condition, prosthesis or procedure previous to initial
diagnosis were excluded from the study. Oral anticoagulant exposure was determined from prescription records in
CPRD by estimating the duration of a prescription as the total prescribed dose divided by a daily dose. A treatment was
considered as being discontinued if the gap between a prescription and a subsequent prescription (or, in the case of
Vitamin K Antagonists (VKAs), a subsequent prescription or INR test) exceeds a grace period of 30 days.
We measured three types of outcomes: (1) death, (2) ischaemic event (which we simply refer to as stroke) and (3)
major bleeding. Patients with any outcome under consideration has taken place within 15 days from the start date were
removed from the study since these endpoints cannot be attributed to treatment effects. A patient is considered loss to
follow-up if (1) dies; (2) leaves the practice or the practice leaves CPRD; (3) discontinues treatment; or (4) at the end of
the study period; whichever happens first. The resulting sample contained 28,972 patients with 48 baseline covariates
including age, gender, key comorbidities and medications and 3 indices of risk of the outcome at baseline, namely the
Charlson index, CHA2DS2-VASc score and HAS-BLED Score. A table with the distribution of baseline covariates can
be found in Appendix C.
4.2 Methodology
As the true contributing feature is unknown, we assess which feature is most frequently identified across multiple
random samples drawn from the whole dataset. In this study, we draw 30 bootstrap random samples of size 8, 000
from 28, 972 observations. An important covariate is expected to be identified in all 30 samples. For visualisation of
confidence interval, we calculate the one-side simultaneous confidence interval, CI∗, as:
CI∗ = CIupper − ψˆ,
where CIupper is the upper 95% simultaneous confidence interval and ψˆ is the estimated effect.
4.3 Results of the case study
Figure 3 depicts the distribution of ITE estimates and corresponding ATE associated with the examined outcomes
(stroke, bleeding, death and combined). As expected, the use of oral anticoagulants confers protection against stroke
and death. On average, patients having anticoagulant are 5.8% (95% CI 4.0%-7.7%) more likely to survive than the
control group at the end of 4 quarters (a hazard ratio (HR) equivalent to 0.44), and 14% (95% CI 9.6%-18.4%) more
likely to survive at the end of 12 quarters (HR: 0.50). The effect on stroke is about 4% (95% CI 1.9%-6.1%) at 12
quarters (HR: 0.56). These equivalent hazard ratios generally agree with previous meta-analysis[42] on the effect of
Aspirin, Warfarin and Ximelagatran in patients with non-valvular atrial fibrillation. Treatment effect heterogeneity
exists although CATE is always positive (CI∗ increases from 1.2% to 4.3% from the end of the first quarter to the 12th
quarter when the outcome is death). The scale of heterogeneity becomes larger with longer follow-up times, but is
accompanied by higher uncertainty, since unmeasured confounding in this framework is more likely to be present with
longer follow-up times.
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Figure 3: Distribution of individual treatment effect (grey violin plots) and average treatment effect estimations (grey cross marks and correspond-
ing values in the squares) with 95% simultaneous confidence interval (black dots).
Table 2: Diagnostic statistics for contributing feature identification
Times indentified Adaptive Lasso BART Causal Forest Elastic Net
Bld Dth Stk Com Bld Dth Stk Com Bld Dth Stk Com Bld Dth Stk Com
Charlson index 30 30 30 30 30 30 30 30 30
Age 30 30 30 30 30 30 30 30
Ticlopidine 30 30 30 30
Vascular disease 29 30 29 30
Female 30 30 30
Hypertension 30 30 30
Cancer (any malignancy) 30 30 30
. . .
Number of Important Covariates 2 7 4 8 7 5 5 5 2 2 1 5 7 4 4 2
Each cell reports the number of times a feature was identified in one of 30 bootstrap random samples of size 8, 000 from 28, 972 estimations
(The max value 30 means that the feature was identified in all samples). The last row reports the number of important covariates identified by
each algorithm on each outcome. Here we show the top seven covariates by the total number of times identified across four outcomes and four
algorithms. The complete table can be found in Table X of Appendix D.
Abbreviations: BLD, Bleeding; DTH, Death; STK, Stroke; COM, Combined Outcomes.
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Table 2 shows the top seven features controlling ITE. Age is the only feature contributing to all outcomes. Charlson
index and cancer with malignancy at baseline are important variables for HTE on bleeding and death. Hasbled score is
important for HTE on bleeding and stroke. When outcomes are combined, important baseline covariates according
to BART (which performed best in our simulation scenarios) are: the Charlson index, age, cancer with malignancy,
CHA2DS2VASc Score and a first AF diagnosis in hospital.
The CATE estimations on four age subgroups (249 observations in [18, 39), 2,992 in [39, 60), 16,587 in [60, 82), and
9,093 in [82, 100]). The largest range of CATEs is observed in relation to the probability of death, which over 24
quarters, varies from 0% to 24.3% for the youngest patients to patients aged 100. This is followed by differences in
CATE for stroke that vary from 0% to 10.4%). This observed HTE is not statistically significant across the smaller age
groups [18, 60). Oral anticoagulants for the group of patients aged 82 and above have a double effect on all outcomes
as compared to their effect on patients aged between 60 to 82. Although the standard error grows with time, it does so
proportionally to the effect size. Across the groups with age greater than 60 and for death and combined outcomes, the
one-side simultaneous confidence intervals (CI∗) are less than 50% of the value of the corresponding CATE estimation
from the second quarter to the 24th quarter.
CATE variations across the Charlson index for death and combined outcomes (see Appendix D) exhibit some non-
linearity over time. For patients with Charlson index greater than 14, the effect on death grows from 0% to the maximum
at the end of the fourth quarter with a difference of 33.8% and dies out to about 11.6% at the 24th quarter. However, this
nonlinearity is not observed in those with Charlson index less than 12. It is worth noting that in this manuscript we report
the simultaneous confidence interval, which is much conservative than the empirical confidence interval calculated
using the standard deviation. For example, the 95% simultaneous confidence interval of the ATE for death outcome at
the end of fourth quarter is (4.0%, 7.7%), whose corresponding empirical confidence interval is (5.6%, 6.0%).
5 Discussion
This article presents a framework to estimate heterogeneous treatment effect in terms of survival probabilities. These
outcomes are popular in the evaluation of medical interventions such as patient survival, cancer recurrence, or
cardiovascular events, which are subject to loss of follow up. In contrast, binary data used in machine learning contains
a finite number of values where censoring is not allowed. Since machine learning methods have been hugely successful
in predicting discrete outcomes, there has been significant interest in applying them to study causal effect in medical
problems, and examples include BART[43], Causal Boosting [44] and Causal Forest [22]. However, these studies have
not explained how to estimate HTE on survival outcomes.
The enormous challenge in the estimation of causal effects on survival data is to incorporate an estimate of the treatment
and censoring mechanism. Existing methods such as Random Survival Forest[45], Super-learner [15] and Deep Neural
Networks[12, 13, 14] only account for the censoring mechanism. Using TMLE allows the efficient estimation of
the average treatment effect as survival probabilities at a single time point by accounting both mechanisms.[19] As
practitioners are often interested in how treatment effect may evolve with time, the study on one-step TMLE demon-
strated how the causal effect could be represented by a monotonic survival curve. But it has not been comprehensively
examined with simulation experiments or typical clinical data like the ones laid out in this paper, neither has it given a
solution to the estimation of effect heterogeneity.
An advantage of our proposed framework is that it reports the effect heterogeneity in terms of the difference in
survival probabilities under treatment and control conditions. This absolute measure is more informative for clinical
decisions compared to relative measures such as the hazard ratio. Secondly, we provide the flexibility of choosing user-
specified methods for potential outcome modelling, important covariates identification and selection bias adjustment.
Thirdly, we automate the heterogeneity discovery process to avoid the ad-hoc selection of subgroups. The adoption of
bootstrap sampling allows the use of BART when the sample size is large, and computing memory is limited. Fourthly,
the adjustment for selection bias was conducted on the identified subgroups to reflect the treatment and censoring
mechanisms within the chosen subgroup.
The challenge of a good survival outcome model lies in the fact that the sample size decreases with time which makes
the estimation later in time highly uncertain. Although Super-learner allows a flexible choice of algorithms for the
best classification, it did not calibrate the model for the optimal probability estimation. We found that increasing
either the sample size or event rate helps to improve the estimation accuracy. On the other hand, the level of treatment
confounding had less impact on the accuracy of CATE than the ATE, even though low confounding scenarios generally
produce better results ceteris paribus. Despite the superior results from using BART, our feature discovery process is
vulnerable to the estimation of ITE, which has high uncertainty and is unadjusted for selection bias. We found that both
linear and non-linear features with a stronger effect on treatment effect are easier to be identified, but over-shadow the
impact of features with less contribution.
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Several important extensions and refinements are left open. This study explores HTE estimation on typical medical
studies where sample sizes are not huge, and there is a moderate amount of meaningful covariates (such as key
comorbidities or risk scores). In future work, we shall explore the usage of the sequential deep learning on high-
dimension observational datasets. We recognise that in estimating heterogeneous treatment effects, the structure of
the potential outcome model matters more than the strategy for handling selection bias. This is because selection bias
is inherently a misspecification problem[18], and hence its impact on non-parametric inference is washed away in a
sufficiently large amount of data with overlap. Nonetheless, in many cases where the sample size is small or a reference
class is not representative, we shall properly account for selection bias. This paper explores the usage of one-step
TMLE, and it would be intriguing to compare it with more recent methods such as the Quasi-Oracle R-learner [17] and
the Non-stationary Gaussian Process Regression (NSGP) [18].
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